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MAJOR PROFESSOR: Dr.  Daotai Nie 
Thromboxane (TX) A2 is a prostaglandin produced by metabolism of arachidonic acid 
through cyclooxygenases and thromboxane synthase. TXA2 is biologically active, mainly 
through activating its cognate, seven transmembrane, G protein coupled receptor. It was 
previously reported that thromboxane A2 receptor (TP) was expressed in prostate cancer, 
and further activation of this receptor elicited cell contraction and modulated tumor cell 
motility through regulating small GTPase RhoA[1]. This study aims to identify G alpha 
protein(s) involved in thromboxane A2 signaling in tumor cell motility.  
Methods: The expression of G alpha proteins in the PC3MM cells was studied by real 
time PCR. Cell contraction assay was performed by staining cells with TRITC phalliodin. 
Tumor cell motility and invasion were evaluated using wound healing assay and 
transwell Boyden Chamber assay. To determine the roles of G alpha protein in 
thromboxane A2 signaling, we expressed different alleles of G alpha proteins (wild type, 
constitutive active) in PC3MM cells and then the subsequent effects on cell contractions 
was determined. We also depleted G alpha protein expression by short hairpin RNA and 
examined subsequent changes in cell contraction and migration after activation of TP. G 
(alpha) 12 has been reported to play critical role in cell proliferation in vitro and tumor 
growth in vivo. These findings were validated by performing BrdU Incorporation assay, 
Cell proliferation assay and cell cycle analysis. Quantitative analysis of the epithelial to 
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mesenchymal transition associated genes was performed by real time PCR. In vivo 
experiments were performed in order to validate in vitro findings.                                          
Results: PC3 MM cell line had the endogenous level of all the G alpha protein (G alpha 
12, G alpha i1, G alpha 11, G alpha 13), but not G alpha q. Overexpression of G alpha 
12/13 increased cell contraction after activation of thromboxane A2 receptor with 
U46619. Expression of constitutively active G alpha 12 by itself was sufficient to cause 
cell contraction, regardless whether TP is activated or not. We have identified two potent 
shRNAs that can silence the G Alpha 12. Depletion of G alpha 12 via shRNAs reduced 
cell contraction after TP activation. Tumor cells with depleted G alpha 12 had shown 
decreased tumor cell motility, invasiveness and cell proliferation. Cell cycle analysis 
showed that G alpha 12 depleted cells exhibit G1/G0 arrest. Quantitative expression of 
EMT associated genes was reduced in G alpha 12 depleted cells exhibiting increase in the 
E cadherin / Vimentin ratio. G alpha 12 depleted cells in comparison to scramble control 
show reduced rate of cell proliferation reminiscent of in vitro findings.                                                                                                                     
Conclusion: This study presents compelling evidence that G alpha 12 plays a major role 
in thromboxane A2 regulation of prostate cancer invasion and metastasis. Silencing of G 
alpha 12 with shRNA may therefore provide a promising therapeutic strategy for prostate 
cancer patients. 
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INTRODUCTION 
Over the years prostate cancer has become the most common male malignancy and one 
of the leading cause of cancer death in American men[2]. Prostate cancer has been 
synonymous with low grade of replication potential along with old age. Median age for 
prostate cancer to develop is around 67 years (SEER Cancer Statistics). Overall there has 
been a decline in the rate of incidence of prostate cancer, it’s not due to the fact that we 
have been able to find a cure for the cancer itself but due to better diagnostic tools or 
screening procedures [3]. Prostate cancer can be diagnosed with blood serum analysis for 
PSA, digital rectal exam and transurethral ultra-sonography (TRUS). Prostate cancer 
substantiates itself with an alteration of Prostate Specific Antigen (PSA) level in the 
blood and urinary dysfunction, along with impact on sexual function and performance. 
The current modalities for treatments include surgery, radiation, and adjuvant hormonal 
therapy. Although these therapies are relatively effective, majority of patients diagnosed 
with localized prostate cancer ultimately recidivate. Therefore, the potential risk 
confronted by prostate cancer patients is the development of metastasis, which presents 
with additional symptoms, such as bone pain, weakness in legs, and urinary and fecal 
incontinence [3]. Immense efforts are underway to develop therapeutics for the treatment 
of prostate cancer metastasis. Epidemiologic studies have shown that individuals who 
take nonsteroidal anti-inflammatory drugs on a regular basis have a 40–50% reduction in 
mortality from colorectal cancer [4]. One trait common in all of the non steroidal anti-
inflammatory drugs is their ability to inhibit cyclooxygenase (COX), an enzyme required 
in the conversion of arachidonic acid to prostaglandins[5]. COX possesses two isoforms, 
COX-1 and COX-2[6]. COX-1 and 2 is expressed at high levels in both bladder and 
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prostate tumors in humans [7], indicating a potential roles for COX in cancer progression. 
Invasiveness of the prostate cancer was reduced by treatment with sulindac sulfone, a 
known COX inhibitor [8]. COX-1 is a constitutively expressed enzyme that generates 
prostaglandins (PG) and thromboxanes from arachidonic acid [5]. Thromboxane synthase 
which originates from arachidonic acid is being known as potent mediator of cancer cells 
metastasis [9]. TXA2 stimulates platelet aggregation which is arbitrated by the activation 
of glycoprotein complex IIb/IIIa[10].TXA2 is  readily hydrolyzed to the biologically 
inactive form TXB2 in aqueous solution[11]. Due to its unstable nature, TXA2 primarily 
functions in an autocrine or paracrine manner within vincity of production [12]. It has 
been shown that low dose of acetylsalicylic acid (asprin) which impedes the formation of 
TXA2 by irreversibly inhibiting cyclooxygenase-1 (COX-1), exhibits 30% reduction in 
colorectal cancer[13] and possibly other cancers and esophageal cancer[4, 14, 15] 
including prostate cancer[13].  
TXA2 is biologically active, mainly through its cognate, seven transmembrane, G protein 
coupled receptor [16]. Ligand binding to the G-protein-coupled receptors (GPCRs) 
transmit signals through conformational changes causing interaction with heterotrimeric 
GTP-binding proteins (G proteins), which in turn activates the downstream signaling 
cascades. After the activation of the receptor these signals are being further carried 
forward by the heterotrimeric G proteins, which are adhered to the inside surface of the 
cell membrane. Heterotrimeric G proteins consist of α, β and γ subunits. Upon activation 
of the G protein coupled receptor it induces a conformational change which manifest 
itself by acting as a guanine nucleotide exchange factor that exchanges  GDP for GTP on 
the G alpha subunit, this action initiates the dissociation of G alpha from Gβγ dimer and 
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its receptor[17] . It is known that thromboxane A2 receptor (TP) which binds to its seven 
transmembrane G protein coupled receptor  is expressed in prostate cancer, and further 
activation of this receptor elicit cell contraction and modulated tumor cell motility 
through regulating small GTPase RhoA[1].  
Based on these findings we hypothesized that G alpha subunits functions as upstream 
regulators of GTPase form of Rho A activity by responding to extracellular stimuli which 
manifest as modulating prostate cancer cell motility and cytoskeleton reorganization. G 
alpha subunit is divisible into four families: G alphas, G alpha i/o, G alpha q/11and G 
alpha12/13.  G alpha12 and Galpha13, are the ones which are activated by various 
stimuli, such as thromboxane A2, lysophosphatidic acid (LPA), and thyroid-stimulating 
hormone receptors[18-22] . G alpha 12 and G alpha 13 are known to modulate variety of 
cellular processes, such as actin cytoskeleton reorganization, neurite retraction, platelet 
aggregation, and apoptosis[19, 21, 23, 24]. In spite of the fact that G alpha12 and G alpha 
13 perform functions that coincide with each other however they seem to distinguish in 
their abilities to conjoin to different ligands for different physiological effectors[18, 21, 
25]. Microarray analysis shows that G alpha12 is highly expressed in nasopharyngeal 
carcinoma [26] and it modulates the actin cytoskeleton reorganization which promotes 
highly invasive nature of these cancer[26, 27].G alpha 12 stimulates multiple signaling 
pathways by the activation of the small GTPase Rho via specific Rho guanine nucleotide 
exchange factors (RhoGEFs)[27]. G alpha 12 stimulate Rho activity through LARG and 
PDZ-RhoGEF[27].p115RhoGEF was the first RhoGEF to be recognized as a connection 
between G alpha 12/G alpha13 and Rho activation[28]. In small cell lung carcinoma, G 
alpha 12 and 13 have been known to promote invasiveness [29]. The ectopic expression 
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of wild-type or an activated mutant of G alpha 12 causes cancerous transformation of 
fibroblast cell lines such as NIH-3T3 cells [30]. Multitude of studies shows that G 
alpha12 and G α13 plays an important role in terms of defining the downstream signaling 
cascade but there role with relation to thromboxane A2 receptor activation was still 
ambiguous in prostate cancer cells. Since it has been proposed that gene modulation is 
one of the most sought after strategy since genomic instability leads to progression of 
cancer which later could result in its metastasis, so knockout experiments were being 
carried out which revealed that G alpha 13 depleted cells resulted in impaired 
angiogenesis and intrauterine death[31]. Knockdown of G alpha 12 has been reported to 
strongly activate the basal ERK, sustained activation of ERK results in DNA damage 
induced apoptosis [32]. These studies reflect that G alpha 12 and G alpha 13 might play a 
pertinent role in cellular signaling pathway in prostate cancer cells. Various methods can 
be employed to inhibit a gene expression, so far small hairpin RNA (shRNA) represents a 
considerable promise for cancer therapy due to its potent and specific knockdown 
effect[33]. In the present study, we intend to silence the G alpha 12 expression in prostate 
cancer cells using synthetic shRNA and evaluate its effects on tumor cell invasiveness 
and growth by employing both in vivo and in vitro experiments. 
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MATERIALS AND METHODS 
Materials 
QS transfection reagent was provided by Dr Yin Yuan Mo. TRIzol reagent, fetal bovine 
serum (FBS), TRITC-phalloidin stain and streptomycin were purchased from Invitrogen 
(Carlsbad, CA).U46619 which is a structural homolog of Thromboxane A2 was purchased 
from Cayman Chemicals (Ann Arbor, MI).Cell culture medium RPMI was purchased 
from Lonza Bio-whittaker (Walkersville, MD).Dulbecco’s Phosphate-Buffered Saline 
(DPBS) and penicillin was obtained from Cellgro (Manassas, VA). Puromycin was 
obtained from Clontech, Inc (Mountain view, CA).Wild type and constitutively active 
form of G alpha subunits (G alpha 12, 13, q, 11 and i1) were purchased from Missouri 
S&T cDNA Resource Center (Rolla, MS).Blocking buffer was purchased from Licor 
Biosciences (Lincoln, Nebraska). SYBR Green-1 dye universal master mix and reverse 
transcriptase were purchased from Takara Biotechnology, Inc. (Otsu, Shiga 
,Japan).Reagents for reverse transcriptase polymerase chain reaction were purchased 
from Thermo Fischer scientific (Barrington, IL) .Falcon Culture cell culture inserts for 24 
well plates with 8.0 µm pore Translucent PET Membrane were purchased from BD 
Biosciences (Mississauga, Ontario). β-actin antibody was purchased from Sigma-Aldrich 
Inc.(St Louis, MO), and the G alpha 12 polyclone antibody was obtained from Santa 
Cruz Biotech. (Santa Cruz, CA). BrdU cell proliferation assay kit was purchased from 
Cell Signaling Technology (Danvers, MA). 
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Cell Culture 
Human prostate cancer cell lines (PC-3MM) were obtained from Dr Kounosuke Watabe. 
PC-3MM cells were cultured in RPMI 1640 with 10% FBS and streptomycin (100 
μg/mL). Cells were cultured in a humidified atmosphere containing 5% CO2 at 37°C. The 
culture medium was replaced every 2–3 days, and the cells were treated with PBS in 
order to lift them up when they reached 80~90% confluence.  
 
Transfection of wild type and constitutively active G alpha subunits 
PC-3MM Cells were transfected with wild type and constitutively active form of G alpha 
subunits (G alpha i1, q, 12, 13 and 11) using QS transfection reagent. Cells were seeded 
in a 6-well plates at a density of 0.5×105 cells/ well in RPMI 1640 medium containing 
10% FBS and streptomycin (100 μg/mL). 1µg of G alpha subunit was mixed with 2 μl 
QS transfection reagent along with 100 μl of FBS free medium RPMI1640, it was 
incubated at room temperature for 15 min to form a complex. The cell culture medium 
was then removed, and 103µl of Gα/QS transfection complex was added drop wise to the 
cells. After twenty-four hours, transfection medium was replaced with fresh RPMI-1640 
medium containing 10% FBS, and streptomycin.  
 
G alpha 12 shRNA Constructs 
Two predesigned commercially available shRNAs (shRNA 909 and shRNA911) were 
purchased from Origene, Inc (Rockville, MD). These shRNAs are of 29 nucleotides each 
one having a sequence as shRNA909 (TGGTGGAGTCCATGAACATCTTCGAGACC) 
and shRNA911 (CTGCTGGAGTTCCGCGACACCATCTTCGA). Both of these 
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predesigned shRNA sequences were verified against the human genome database to 
annihilate cross linking with other-target genes. Scrambled shRNA was purchased from 
Origene, Inc and it was used as a negative control. 
 
Transfection of G alpha12 shRNA 
PC-3MM Cells were transfected with shRNA using QS transfection reagent. Cells were 
seeded in a 6-well plates at a density of 0.5×105 cells/ well in RPMI 1640 medium 
containing 10% FBS and penicillin/streptomycin (100 μg/mL). After 24 hours, cells were 
transfected with shRNA using QS transfection reagent. 1µg of shRNA was mixed with 2 
μl QS transfection reagent along with 100 μl of FBS free medium RPMI 1640; it was 
incubated at room temperature for 15 min to form a complex. The cell culture medium 
was then removed, and 103µl of shRNA/QS transfection complex was added drop wise 
to the cells. After twenty-four hours, transfection medium was replaced with fresh RPMI-
1640 medium containing 10% FBS, and streptomycin.  
 
Real-Time RT-PCR 
Total RNA was isolated from cell pellets using TRIzol reagent (Invitrogen) as per the 
manufacturer’s protocol. RNA (1µg) was converted to cDNA using dNTP, primers, and 
Taq polymerase Reverse Transcriptase Reagent. One microgram of cDNA was amplified 
by Real-Time PCR using the MJ Mini Thermal Cycler (Biorad Life Sciences, Hercules, 
CA).GAPDH was used as a loading control. The primers used for G alpha subunits are as 
follows 
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G alpha q 5′-TGGGTCAGGATACTCTGATGAAG-3′(forward) and 5′-
TGTGCATGAGCCTTATTGTGC-3′ (reverse)  
G alpha i1 5′-GCTCAACCAAATTACATCCCGA-3′(forward) and 5′-
TCGTAGTCACTCAGTGCTACAC-3 (reverse) 
G alpha 11 5′-CCAAGCTCGTCTACCAGAACA-3′(forward) and 5′-
TGACGTACTGATGCTCGAAGG-3 (reverse) 
G alpha 13 5′-TCCAAGGAGATCGACAAATGC-3′(forward) and 5′-
CCAGCACCCTCATACCTTTGA-3 (reverse) 
G alpha 12 5′-AAGGGCTCAAGGGTTCTTGTT-3′(forward) and 5′-
TGATGCCAGAATCCCTCCAGA-3 (reverse). 
To confirm the knockdown of G alpha 12 we performed quantitative PCR, 1 microgram 
of cDNA was amplified using SYBR Green Master mix on 7500 Real Time PCR System 
by Applied Biosciences (Foster City, CA).  PCR products were subjected to a melting-
curve analysis. Comparative threshold (Ct) method was used to calculate the relative 
amount of mRNA of treated sample in comparison to control samples. Each sample was 
performed in triplicate, and the mean value was calculated. 
 
Cell Contraction Assay 
PC-3MM cells (10,000 cells/well) were plated at low density in 6 well plate and 
incubated at 37
o 
C in a humidified environment having 5% of CO2. Cells were placed 
under serum free condition for 24 hours. Replace the media and put 300nMol U46619 
(structural analog of TXA2) for 15 min. Removed the media and add 2% paraformaldehye 
for 15 min. Wash the cells with PBS for 15 min. Treated the cells with 0.1x of triton. 
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Removed triton and washed the cells with PBS for 1 min. Treated the cells with TRITC 
phalloidin stain for 15 min, remove the staining media and wash the cells with PBS for 
15 min. Images were taken  using an inverted microscope. 
    
Western Blot Analysis 
PC-3MM cells transfected with the G alpha 12 shRNA for 24 h, 48 h post transfection, 
protein was isolated using 2x SDS buffer which contains protease and phosphtase 
inhibitor. Same amount of total protein was used for all the samples and was separated on 
a SDS PAGE gel (percentage of gel depended on the molecular weight of the protein). 
The separated proteins were transferred to a nitrocellulose membrane, blocked, and 
probed with appropriate antibodies. The protein bands were then visualized using 
secondary antibodies. The membranes were later scanned with Odyssey infrared 
analyzer. 
 
Wound-Healing Assay 
PC-3MM cells were seeded in 6-well plates, Once the cells reached 90% confluency, 
using a (yellow) pipette tip make a straight scratch which simulates a wound by keeping 
the tip under an angle of around 30 degrees to keep the scratch width limited. The 
detached cells were removed by washing with PBS. Then, the cells were incubated in the 
incubator supplemented with 5% CO2 at 37°C. The wound-healing process was 
monitored microscopically over the period of time as the cells moved into the wound 
area, and the images were taken from the same place at various intervals using an 
inverted microscope.  
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Cell Migration Assay  
The effect of shRNA on invasiveness and metastatic potential of prostate cancer cells was 
evaluated using Boyden Chamber assay .Twenty-four hours after seeding the PC-3MM 
cells. They were treated with PBS in order to lift them up and later it was re-suspended in 
FBS-free RPMI- 1640 medium. A total of 5×103 PC-3MMcells were suspended in 200 μl 
volume of serum free RPMI 1640 were plated in the top chamber with an un-coated  
membrane (0.3cm2 growth surface, 8.0 μm pore size, Polyethylene terephthalate) for 
migration assay.10% FBS containing RPMI1640 was added in the lower chamber as a 
chemo-attractant. After incubation for 24 h, the cells migrated to the lower surface of the 
membrane .The cells that did not migrate through the pores were mechanically removed 
with a cotton swab. After 18 hours of treatment, images of migrated cells were obtained 
by an inverted microscope at a magnification of 200x. 
  
BrDU Incorporation Assay 
PC-3MM cells (10,000 cells/well) were plated in 96 well plate and incubated at 37
o 
C in a 
humidified environment having 5% of CO2. BrdU solution was prepared by diluting the 
1000X stock in cell culture medium at 1:100 dilutions. After 24 hours, remove media that 
contains BrdU solution. After adding 100µl of the fixing solution incubate the plate at 
room temperature for 30 min. Remove solution and add 100µl/well of premade 1x 
detection antibody solution. Keep the plate at room temperature for 1 hour. Remove 
solution and wash plate with 1 x wash buffer. Now add 100µl/well prepared 1x HRP- 
conjugated solution and keep it at room temperature for 30 min. Remove the solution and 
wash plate with 1 x wash buffer. Add 100µl of TMB substrate. Incubate the plate for 30 
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min. Keep an eye on color change as it may be imperative to stop the reaction prior to 
development time of 30 min. Add 100µl STOP solution. Read absorbance at 450nm 
within 30 min for optimal results.    
 
Cell Proliferation Assay 
PC-3MM cells (100000 cells/well) were plated in triplicate at a low density in a 6-well 
plate and incubated for 24 hours in serum containing RPMI 1640 medium. The incubated 
cells were treated with 1 ml of PBS at 24, 48 and 72 hours in order to detach the cells for 
counting. The cells are being treated with trypan blue which stains the damaged cells and 
count viable cells that exclude the dye. The effect of G alpha 12 shRNA on cell 
proliferation was measured using Beckman Coulter Vi-cell Cell Viability Analyzer (GMI 
Inc. Minneapolis, MN).  
   
MTS Assay 
MTS assay is a colorimetric method for evaluating the number of viable cells in culture. 
The MTS compound is reduced by viable cells into a colored formazan product that is 
soluble in tissue culture medium. The quantity of formazan is directly proportional to the 
number of living cells present in culture which can be recorded at 490nm of 
absorbance.PC-3MM cells (10000cells/well) were seeded in at low density in triplicate in 
a 96-well plate. The cells were incubated in a humidified environment in 5% CO2 at 37
o
 
C. The incubated cells were treated with MTS solution after 48 hours. Absorbance was 
recorded at 490nm within 30 min for optimal readings. The effect of G alpha 12 shRNA 
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on cell proliferation was measured using Thermo Elektron Corporation (Multiskan 
Spectrum).  
 
Cell Cycle Analysis Assay 
PC-3 MM cells transfected with G alpha 12 shRNA were incubated at 37
o
C in a humid 
environment having 5% CO2 .When cells reached 80~85% confluency, they were 
detached by PBS, cells were collected and centrifuged at 1200 rpm at 4
o
C for 5 min, 
decant supernatant and gently re-suspend the cells in PBS. To fix the cells add 0.7ml in 
ice-cold 70% ethanol and leave it on ice for 1hour. After fixing, cells were washed with 
PBS once and then re-suspend cell pellet in 0.25ml of PBS, add 5µl of 10mg/ml Rnase A. 
Incubate it at 37
 o
C for 1 hour. Add 10 µl of 1mg/ml PI solution. Keep it under cover and 
at 4
o
C until analysis.  Cell cycle analysis was carried out with FACS Flow cytometer (BD 
Biosciences) at 488nm. The result was confirmed from three independent experiments; 
each group had three samples. 
 
Tumor cell lines & in vivo experiments 
The PC-3MM cell lines were cultured in RPMI 1640 supplemented with 10% fetal 
bovine serum and penicillin/streptomycin(100µg/ml).Animal use was according the 
guidelines set by  Animal Welfare Act(AWA)/United States Department of Agriculture 
(USDA).For induction of tumors nude mice were injected subcutaneously with 2x10
6
 
scramble control as well G alpha 12 depleted PC-3MM cells at the back. The rate of 
tumor growth was monitored for 4 weeks.  
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Statistical Analysis 
Student’s t test was employed to examine the difference between two groups. Data was 
expressed as the mean ±standard deviation (SD). P<0.05 was considered statistically 
significant. 
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RESULTS 
Endogenous expression of G alpha subunits in PC-3MM 
The endogenous expression of G alpha subunits was analyzed by real time PCR.G alpha 
subunits were amplified from the cDNA which was synthesized from mRNA by reverse 
transcriptase PCR. As shown in fig 1, All cell lines tested had the endogenous expression 
of all the G alpha subunits (G alpha 12, G alpha i1, G alpha 11, G alpha 13 and G alpha 
q), with the exception that PC 3 and PC3 MM cell lines which lacked G alpha q as shown 
in Fig 1. 
 
G alpha12 and G alpha 13 activation causes actin cytoskeletal reorganization 
In order to determine the role of G alpha subunits in thromboxane A2 signaling, we 
expressed different alleles of G alpha proteins (wild type, constitutive active) in PC3MM 
cells and then the subsequent effects on cell contraction were determined. The rationale 
behind transfecting the constitutively active form was to use it as a reference control 
since it would exhibit its effect even in the absence of the ligand. It was observed that 
overexpression of G alpha 12/13 increased cell contraction after activation of 
thromboxane A2 receptor, when treated with U46619. Expression of constitutively active 
G alpha 12 (Fig 2A) or G alpha 13 (Fig 2B) was sufficient to cause cell contraction, 
regardless whether TP is activated or not. Cells that exhibited rounded morphology 
having the length twice less than its width were counted.  
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Inhibition of U46619 induced cell contraction by G alpha Q 
Profiling of G alpha subunits revealed a loss of G alpha Q in PC-3 or PC-3MM cells. 
U46619 induces cell contraction in PC-3 or PC-3MM cells efficiently but not in DU145 
cells, even though DU145 cells express receptors for thromboxane A2. We hypothesize 
that G alpha Q may attenuate TP signaling to cell contraction. To test this hypothesis, 
PC-3MM cells were transfected with expression constructs for G alpha Q or 
constitutively active G alpha Q and then treated with U46619. Cells were then fixed, 
stained, and scored for contraction. As shown in Figure 3, restoration of G alpha Q or 
expression of active G alpha Q blocked U46619 induced cell contraction. Untransfected 
cells were used as controls. The results suggest that G alpha Q subunit inhibits U46619-
induced cell contraction. 
  
Suppression of G alpha 12 with commercially available shRNAs  
Two commercially prepared synthetic shRNAs that would target human G alpha 12 
mRNA were transfected in PC-3 MM cells. Suppression of G alpha 12 was examined in 
PC-3MM cells by shRNAs at the mRNA level using real-time RT-PCR. A scrambled 
shRNA was used as a negative control. Compared to the scrambled shRNA, both shRNA 
909 and shRNA 911 exhibited an efficacious suppression of G alpha 12. Furthermore, the 
suppression of G alpha 12 at the protein level was confirmed by western blot. As shown 
in Fig 4, both shRNA909 and shRNA911 dramatically depleted the G alpha 12 protein 
expression in PC-3MM cells, which is consistent with the suppression at the mRNA 
level.  shRNAs constructs were further used for following biological studies in prostate 
cancer cells.  
16 
 
 
 
G Alpha 12 depleted cells inhibit actin cytoskeleton reorganization  
Inhibition of G alpha 12 decreased cell contraction after activation of thromboxane A2 receptor 
with U46619. Cells were transfected with short hairpin RNA for G alpha 12, in the presence of a 
GFP marker construct pEGFP, and then serum starved for 24 hours. Cells were treated with 
U46619 and EtOH for 15 min. fixed and then stained with TRITC phalloidin staining. As shown 
in Fig 5, scramble control cells in comparison to stable knock down of G alpha 12 showed greater 
contracting ability. Contractions of cells, transfected or untransfected, were scored under an 
epifluorescence microscope. 
Suppression of G alpha 12 Inhibits Cell Motility 
We investigated the effect of G alpha 12 inhibition on cell motility and invasiveness of 
prostate cancer cells. Wound-healing assay is an in vitro assay which portrays the in vivo 
motility of cancer cells. When cells reached 90% of confluency, they were disrupted by 
scratching a line through the layer to simulate a wound in the cell monolayer. The rate of 
cell migration is measured by the amount of time required to fill the gap and it depicts the 
wound healing process. Cells having depleted G alpha 12  showed slower rate of 
migration as compared to the cells treated with scrambled shRNA when treated with 
U46619(structural analog of TXA2). After 8 hours, cells transfected with the scrambled 
shRNA had filled the gap about 75~80%, while the cells treated with the G alpha 12 
shRNA still had an unhealed gap (Fig 6), indicating that depletion of G alpha 12 can 
efficiently suppress the motility of prostate cancer cells.  
 
Depletion of G alpha 12 inhibits cell migration  
We investigated the effects of G alpha 12 depletion on the migrating abilities of prostate 
cancer cells. Migration of metastatic tumor cells towards a chemo-attractant is trademark 
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of these cells, and it is considered to be an essential step for tumor invasion and 
metastasis. The migration ability of PC-3MM cells was analyzed using Boyden chamber 
assay, which is a model to imitate the in vivo metastatic process. As shown in Fig.7, the 
scramble control cells treated with U46619 shows enhanced capability for migration in 
comparison to the cells having a stable knockdown of G alpha 12. Stable knockdown of 
G alpha 12 restricted the migrating ability of PC-3MM cells to 15% and 12%, 
respectively. 
 
Effect of G alpha 12 shRNA on Cell Proliferation  
Having shown that suppression of G alpha 12 refrains the cancer cells from acquiring 
migratory property, we performed three assays to examine the effects of  G alpha 12 
depletion on the rate of proliferation of prostate cancer cells. It was observed that G alpha 
12 depleted PC-3MM cells exhibited slower rate of growth and viabilities when 
compared to cells transfected with scrambled shRNA, These findings were consistent in 
all the three assays (MTS assay, BrdU incorporation and trypan blue cell proliferation 
assay) as shown in fig 8. 
             
Effect of G alpha 12 depletion on Cell cycle 
We performed cell cycle analysis to determine whether knockdown of G alpha 12 
precede to changes in the cell cycle distribution of prostate cancer cells. Cells transfected 
with G alpha 12 shRNAs in comparison to scrambled shRNA treated cells effectuate a 
block in G1/G0 phase distribution. The percentages of cells in G1/G0 phase in cells 
having depleted G alpha 12 for both the clones (shRNA 909,shRNA 911) were 53% and 
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64% , whereas 44% having scrambled shRNA were in G1/G0 phase. This G1/G0 phase 
was accompanied by repression in G2/M and S phase distribution in both G alpha 12 
depleted cells. This difference in G1/G0 phase is statistically significant (p=0.05). The 
results of cell cycle analysis are consistent with findings of the cell proliferation assay. 
These results demonstrated that G alpha 12 inhibition negatively regulates cell 
proliferation in prostate cancer as shown in Fig 9.   
 
Effect of G alpha 12 inhibition on EMT associated genes 
Whenever a metastasis takes place in primary cancer it is always preceded by a 
complimentary change which is called as epithelial to mesenchymal transition (EMT). 
EMT causes transient morphologic and biological changes in cells that will alter cell 
motility and contact with neighboring cells[34]. The knockdown of G alpha 12 in PC-3 
MM causes increased expression of all those markers which causes increased cell-cell 
interaction such as E cadherin and claudin 1 along with concomitant decrease in the 
expression of the vimentin, snail, snail 2, beta catenin, MMP9, MMP2(matrix 
metalloprotease), Zeb 1(Zinc finger E box binding homeobox binding 1), fn 
1(fibronectin), fsp 1(fibroblast secretory protein) and sip 1 (Fig 10). These results were 
further verified by western blot. Taken together these results reflect that inhibition of G 
alpha 12 reduces EMT. 
 
Effects of G alpha 12 suppression on tumor growth and progression 
In order to confirm our in vitro findings we carried out in vivo experiments in nude mice. 
2x10
6 
cells having scramble control and G alpha 12 depleted cells were injected 
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subcutaneously in mice. The rate of growth of tumor was monitored for a period of 4 
weeks. As shown in fig 11, scramble control cells showed robust rate of tumor growth as 
compared to the depleted G alpha 12 cells. These findings were consistent with our in 
vitro findings.       
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DISCUSSION 
It is known that in order to metastasize, cancer cells need to acquire motility. During cell 
migration, a cell contracts at the trailing edges. Cytoskeleton reorganization is also 
required for the the formation of lamellipodia and fillopodia (cytoskeleton actin 
protein)[35]. Rho A is a small GTPase regulated protein known to control the actin 
cytoskeleton structure which results in the formation of stress fibers. Rho A modulates 
the actin cytoskeleton reorganization by activating ROCK which ends up activating 
cofilin through LIM kinase activation [36]. 
It has been shown that  TXA2 by binding to its cognate G protein coupled receptor causes 
the  activation of RhoA which goes on to bring about actin cytoskeleton reorganization 
and manifests in the form of cell motility[1]. Since G protein coupled receptors 
channelize there activation through the heterotrimeric G proteins so we proposed that G 
alpha subunits might be the one regulating the downstream signaling of Rho A. 
Principally there are four different G alpha subunits which can regulate the downstream 
signaling cascade such as G alpha s, G alpha i/o, G alpha q/11and G alpha12/13. We 
were not sure as to which subunit is regulating the activation of RhoA when TXA2 ligand 
binds to its receptor.  
In this study we explored that activation of the G alpha subunit is a critical step in the 
activation of Rho A and G alpha 12 is an important upstream regulator of the Rho A 
activation. G alpha 12 has been identified to play a major role in the metastasis of breast 
and nasopharyngeal cancers[26], though there role was still undeterminate in prostate 
cancer in relation to activation through TXA2.  
In this study, we demonstrated that G alpha 12 shRNA even in the presence of U46619 
(structural analog of TXA2) significantly decreases invasiveness of prostate cancer cells. 
21 
 
 
 
We examined the effect of G alpha 12 depletion by two predesigned shRNAs in prostate 
cancer cells which was verified using real time RT-PCR and western blot analysis. Two 
commercially prepared potent shRNAs, shRNA- 909 and shRNA-911 were utilized to 
investigate their biological effects on prostate cancer cells. It is generally believed that G 
alpha 12/13 promotes the invasiveness as well as cell proliferation human small cell lung 
carcinoma in vitro and tumor growth in vivo[29]. We then analyzed the effect of G alpha 
12 silencing on the invasive properties of prostate cancer by conducting wound-healing 
assay and chamber migration assay. Our studies showed that silencing of G alpha 12 
significantly inhibit the would-healing process as well as cell migrating ability of prostate 
cancer cells as shown in Fig.4. The ability of the cells to close the gap with subsequent 
establishment of new cell-cell contacts depicts the migratory capability of cancer cells in 
metastasis. We further evaluated the migratory ability of prostate cancer cells having 
depleted G alpha 12 using a Boyden chamber assay. As shown in Fig6, G alpha 12 
shRNAs significantly inhibited the migration capability of PC-3MM cells. These results 
are in full agreement with a recent finding that G alpha 12 promotes prostate cancer 
metastasis [27].  
Kumar and colleagues reported the role of G alpha 12 in soft tissue sarcomas as to be  a 
putative causative oncogene and over expression of  wild type or GTPase deficient 
mutant of G alpha 12 causes oncogenic transformation of NIH3T3 cells[37]. This 
oncogenic transformation in NIH3T3 cells manifests by increased rate of cell 
proliferation, anchorage independent growth, decreased growth factor dependency and 
cytoskeletal changes [34]. They showed that suppression of PDGFR alpha and JAK3 
rarefied the mutant G alpha 12 activity [34]. So they proposed that PDGFR alpha and 
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JAK3 provide an autocrine/paracrine loop for activation in G alpha 12 mediated cell 
proliferation. Based on these findings we performed three assays(MTS assay, BrdU 
Incorporation assay and Trypan blue cell proliferation assay)  to depict the effect of G 
alpha 12 inhibition on the rate of cell proliferation in PC-3MM cells. As expected 
scramble control cells showed greater rate of cell proliferation as compared to the cells 
having a stable knockdown of G alpha 12.  This result is in conformity with a report that 
knockdown of PDGFR alpha and JAK3 attenuated G alpha 12 and affected the rate of 
cell proliferation [3] . To further confirm these results, we performed cell cycle analysis. 
We observed that cells having a stable knockdown of G alpha 12 in comparison to 
scramble control showed slightly high distribution in G1/G0 phase, with a concomitant 
decrease in the cell population in S and G2/M phase. The difference is statistically 
significant from the control group. These results suggest that G alpha 12 shRNA has a 
significant effect on cell proliferation of PC-3MM cells.  
Recently it has been reported that invasive phenotype is necessary for cells to cause bone 
metastasis[38]. Epithelial to mesenchymal transformation(EMT) in prostate cancer cells 
plays a pertinent role in not only prostate cancer maintenance but also bone metastasis 
and it is functionally associated with prostate cancer stem cells[38]. So we performed a 
quantitative analysis for the EMT associated genes, results show that G alpha 12 depleted 
cells in comparison to scramble control cells showed higher expression of those genes 
which modulates the cell- cell interaction (e cadherin and claudin) as a consequence it 
increased the E cadherin/vimentin ratio hence trying to restrict cells from acquiring 
mesenchymal trait which modulates the metastatic potential of prostate cancer cell line. 
We performed in vivo experiments in order to validate our in vitro findings. In vivo 
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studies carried out suggest that silencing of G alpha 12 and 13 leads to reduced tumor 
growth in comparison to control cells in Small cell lung carcinoma (SCLC) [29]. Results 
acquired after 4 weeks reflect that mice injected with knockdown clones of G alpha 12 
showed slower growth rate in comparison to control cells.  
In summary, results from this study provided significant evidence that G alpha 12 plays a 
pivotal role in the metastasis of prostate cancer cells. Considering the fact that the major 
risk faced by prostate cancer patients is the development of metastasis [39], the G alpha 
12 shRNA may provide a very promising approach for prostate cancer therapy. 
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Fig 1. Expression profile of different G alpha sub-unit in benign and malignant cell lines. 
G alpha subunits were amplified from the cDNA generated by reverse transcriptase from 
mRNA. GAPDH was used as a loading control.   
 
     
  
25 
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Fig 2. Overexpression of G alpha 12 (A) increased cell contraction after activation of 
thromboxane A2 receptor with U46619. Cells were transfected with expression vector for G 
alpha 12/13 or active G alpha 12/13, in the presence of a GFP marker construct pEGFP, and 
then serum starved for 24 hours. Cells were treated with U46619 and EtOH for 15 min. fixed 
and then stained with TRITC phalloidin staining. Contractions of cells, transfected or 
untransfected, were scored under an epifluorescence microscope. 
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B)
Fig 2. Overexpression of G alpha 13 (B) increased cell contraction after activation of 
thromboxane A2 receptor with U46619. Cells were transfected with expression vector for G 
alpha 12/13 or active G alpha 12/13, in the presence of a GFP marker construct pEGFP, and 
then serum starved for 24 hours. Cells were treated with U46619 and EtOH for 15 min. fixed 
and then stained with TRITC phalloidin staining. Contractions of cells, transfected or 
untransfected, were scored under an epifluorescence microscope. 
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Fig 3. Suppression of U46619-induced contraction by G alpha Q. Cells were transfected with 
expression vector for G alpha Q or active G alpha Q, in the presence of a GFP marker 
construct pEGFP, and then serum starved for 24 hours. Cells were treated with U46619 and 
EtOH for 15 min. fixed and then stained with TRITC phalloidin staining. Contractions of 
cells, transfected or untransfected, were scored under an epifluorescence microscope. 
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Fig 4. Suppression of G alpha 12 by pre-designed shRNA in PC-3 MM cells. 
Validation of suppression of G alpha 12 at the mRNA level was done by (a) 
Quantitative PCR and (b) RT PCR. Suppression of G alpha 12 at protein level was 
confirmed by (c) Western blot.  (*p<0.05;**p<0.005;***p<0.0005)  
(a)                                                             
(b)                                                             (c)                                                             
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Fig 5. G Alpha 12 depleted cells do not contract when treated with U46619. Inhibition of G 
alpha 12 decreased cell contraction after activation of thromboxane A2 receptor with 
U46619. Cells were transfected with short hairpin RNA for G alpha 12, in the presence of a 
GFP marker construct pEGFP, and then serum starved for 24 hours. Cells were treated with 
U46619 and EtOH for 15 min. fixed and then stained with TRITC phalloidin staining. 
Contractions of cells, transfected or untransfected, were scored under an epifluorescence 
microscope. 
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Fig6. Effect of suppression of G alpha 12 on cell motility. Wound healing assay was 
performed in order to ascertain the effect on cell motility in PC-3 MM cells after silencing G 
alpha 12.PC-3 MM cells were seeded in a 6 well plate. Cell monolayer was disturbed by 
producing a scratch when cells reached 90% confluency. After 8 hours, scramble control cells 
which were treated with U46619 showed increased ability to close the gap in comparison to 
the cells which had a stable knock down of G alpha 12.Closing of the gap was closely 
monitored at different time points using an inverted microscope at 200x. 
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Fig 7. Effect of G alpha 12 
suppression on cell migration. 
Boyden chamber assay was 
performed to ascertain the effect. 
Cells are placed in serum free 
condition in upper chamber and 
lower chamber contains 10% FBS 
which acts as a chemo-attractant. 
Images of migrated cells were 
taken by inverted microscope at 
magnification of 200x.    
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(b) BrDU Incorporation Assay: 
10000 cells/well were plated in 
96-well plate and incubated for 
24 hours in serum containing 
medium. After 24 hours, the 
incubated cells were treated with 
BrdU solution 100X for 24 hours. 
Absorbance was recorded at 
450nm. 
Fig 8. (a) MTS Assay The effect 
of shRNA on cell proliferation 
was measured using MTS 
Assay.PC-3MM cells 
(10000cells/well) were seeded in 
a 96-well plate. The incubated 
cells were treated with MTS 
solution after 48 hours. 
Absorbance was recorded at 
490nm.  
 
(c) Trypan blue cell proliferation assay 100000 cells/well were plated in 6-
well plate and incubated for 24 hours in serum containing medium. The 
incubated cells were harvested at 24 ,48 and 72 hours. The number of cells 
were counted by Cell Viability Chamber at respective time points.  
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Fig 9. Effect of G alpha 12 silencing on cell cycle distribution. Cell cycle 
distributions were determined by flow cytometry in PC-3 MM cells at 48 
hours post-incubation. Inhibition of G alpha 12 in PC-3MM results in G1/G0 
arrest accompanied by concomitant decrease in S and G2-M phase. 
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Fig 10. G alpha 12 regulates EMT in PC3 MM cell line. (a) Western blot depicting 
knock down of G alpha 12 causes up regulation of E cadherin expression along with 
complimentary decrease in β catenin and vimentin.(b)The mRNA expression level of 
different EMT associated genes in G alpha 12 depleted cells in PC-3 MM. 
(a) (b) 
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Fig 11. Growth kinetics from our in vivo experiments. (a)Tumor size and (b) Tumor 
Volume were determined by caliper measurements. Tumors were caliberated for four 
weeks in two dimension (Length x Width) and tumor volume was calculated by the 
formula as Length x Width x Width/2 
(a) (b) 
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